Project Grant K99HL181288
Award Date 9/19/25
Completion Date 8/31/27
Dollars Obligated $169K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award of $744,692.00, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on August 15, 2025, supports research into the mechanical regulation of cardiac growth and remodeling by VCAN-GPR126 signaling. The research aims to test the hypothesis that VCAN-GPR126 signaling is stimulated by mechanical forces during both cardiac development and postnatal remodeling. Key objectives include using conditional and mutant...
- This federal Project Grant award of $248,431 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by The Johns Hopkins University aimed at elucidating the role of microenvironment mechanics in regulating cardiac myofibroblast plasticity. The 5-year research plan leverages human induced pluripotent stem cell-derived cardiac fibroblasts, engineered biomaterials with tunable mechanical properties, and single-cell multiomics...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $1,137,498 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of the University of Pennsylvania for the project "Locking and Unlocking Cardiac Maturation". The project aims to investigate the regulatory mechanisms involved in the developmental maturation of the heart, with the goal of improving understanding of genetic...
- This $240,552 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to generate a comprehensive single-cell transcriptomic and regulomic map of human bone marrow cells, as well as experimentally establish the mesenchymal hierarchy in human bone. The project will utilize protocols to isolate single-cell suspensions from human femoral head tissue and enrich for rare or difficult-to-isolate cell populations such as...
- This $149,804 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research on the structural and functional features of the native cardiac sarcomere in hypertrophic cardiomyopathy (HCM). The project aims to directly observe the conformational changes in the beta-myosin motor protein caused by HCM-inducing mutations and the FDA-approved drug mavacamten, using advanced cryo-electron tomography...
- The National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $167,400 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dr. Joshua Meisner at the University of Michigan. The award aims to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy caused by truncating variants of the MYBPC3 gene, a leading cause of sudden cardiac death and heart failure, especially in children and adolescents....
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $694,754 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Washington University in Missouri. The 5-year grant, which commenced on August 1, 2025, will support research to investigate the fundamental molecular mechanisms driving the pathogenesis of key troponin cardiomyopathy mutations and their effects on cellular and tissue function. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $811,885 in funding to the J. David Gladstone Institutes in San Francisco, California. The award supports research to investigate the epigenomic mechanisms governing cardiac fibrosis and heart failure pathogenesis. Key goals include understanding the role of the MEOX1 transcriptional regulator in fibroblast activation and fibrosis, with...
- The University of Pennsylvania was awarded a $667,704 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop chemically inducible split base editors for precise and controllable in vivo genome editing. The goal is to create improved base editors that can safely and effectively correct gene mutations underlying hypertrophic cardiomyopathy, a common inherited heart disease, without the safety concerns...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...